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Abstract
Background: Mass treatment with ivermectin is a proven strategy for controlling onchocerciasis as a public health problem,
but it is not known if it can also interrupt transmission and eliminate the parasite in endemic foci in Africa where vectors are
highly efficient. A longitudinal study was undertaken in three hyperendemic foci in Mali and Senegal with 15 to 17 years of
annual or six-monthly ivermectin treatment in order to assess residual levels of infection and transmission and test whether
ivermectin treatment could be safely stopped in the study areas.
Methodology/Principal Findings: Skin snip surveys were undertaken in 126 villages, and 17,801 people were examined.
The prevalence of microfilaridermia was ,1% in all three foci. A total of 157,500 blackflies were collected and analyzed for
the presence of Onchocerca volvulus larvae using a specific DNA probe, and vector infectivity rates were all below 0.5
infective flies per 1,000 flies. Except for a subsection of one focus, all infection and transmission indicators were below
postulated thresholds for elimination. Treatment was therefore stopped in test areas of 5 to 8 villages in each focus.
Evaluations 16 to 22 months after the last treatment in the test areas involved examination of 2,283 people using the skin
snip method and a DEC patch test, and analysis of 123,000 black flies. No infected persons and no infected blackflies were
detected in the test areas, and vector infectivity rates in other catching points were ,0.2 infective flies per 1,000.
Conclusion/Significance: This study has provided the first empirical evidence that elimination of onchocerciasis with
ivermectin treatment is feasible in some endemic foci in Africa. Although further studies are needed to determine to what
extent these findings can be extrapolated to other endemic areas in Africa, the principle of elimination has been
established. The African Programme for Onchocerciasis Control has adopted an additional objective to assess progress
towards elimination endpoints in all onchocerciasis control projects and to guide countries on cessation of treatment where
feasible.
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Introduction
Onchocerciasis control strategies have evolved significantly over
the last three decades. The Onchocerciasis Control Programme in
West Africa (OCP) [1], launched in 1975, used aerial larviciding of
vector breeding sites in river rapids. This strategy was very successful
in interrupting onchocerciasis transmissionandultimately eliminating
the disease as a public health problem in the savanna areas of 10 West
African countries [2]. However, aerial larviciding was not considered
feasible or cost-effective elsewhere in Africa and in the absence of a
drug that could be safely used in mass treatment, nothing was done to
fight this debilitating disease in the rest of the continent where over
85% of the 37 million infected persons lived [3].
This situation changed dramatically in 1987 with the registra-
tion of ivermectin for the treatment of human onchocerciasis, and
its donation free of charge for as long as needed by the
manufacturer of the drug [4]. This revolutionized the fight against
the disease, and led to the creation of the African Programme for
Onchocerciasis Control (APOC) [5] that covered all the remaining
onchocerciasis endemic areas in Africa, and the Onchocerciasis
Elimination Programme for the Americas (OEPA) [6]. Currently,
onchocerciasis control is nearly exclusively based on annual or six-
monthly ivermectin treatment of all eligible members of
communities at risk.
By the time APOC was launched in 1995, it was known from
clinical and community trials that ivermectin was highly effective
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disease, and hence that mass treatment with ivermectin was an
effective strategy for controlling the disease as a public health
problem [7–9]. But research had also shown that the drug had
limited effect on the viability and productivity of the adult
onchocercal worms which resumed production of microfilariae a
few months after treatment [10], making it necessary to repeat
treatment at intervals of no longer than one year to maintain
microfilarial loads below levels of public health concern.
Community trials had shown that mass treatment with ivermectin
significantly reduced but did not interrupt onchocerciasis trans-
mission during the first years of treatment, and given the adult
worm life expectancy of about 10 years on average, it was
concluded that annual treatment needed to be continued for a
very long period of time [11]. Hence APOC’s principal aim was to
establish and sustain high treatment coverage in all areas where
onchocerciasis was a public health problem [12]. To achieve this,
APOC supported the establishment of community-directed
treatment with ivermectin (CDTi) in all APOC countries [13,14].
However, the question of whether, and if so when, the parasite
could ultimately be eliminated with ivermectin treatment, and
treatment safely stopped, remained unanswered at that time. Initial
computer simulations with the model ONCHOSIM that were
based on the results of the first community trials of ivermectin and
the assumption that ivermectin is only a microfilaricide, predicted
that annual treatmentmayneededtobecontinuedformorethan 25
years [11]. When subsequent studies after five years of treatment
indicated that ivermectin treatment also reduced the fertility of the
adult worms by some 30% after each treatment, these predictions
were revised downward [15,16]. However, this cumulative
reduction in adult worm reproductivity was not seen in another
study [17] and the predictions remained untested. Although it was
generally believed that elimination would be possible in most of the
Americas where onchocerciasis foci are often small and circum-
scribed, and several (though not all) vector species are relatively
inefficient, there remained considerable uncertainty as to whether
ivermectin treatment could ever achieve sustained interruption of
transmission in Africa where onchocerciasis is endemic over vast
areas and where all vectors are highly efficient [18–20].
Among the areas where large-scale ivermectin treatment was first
introduced inAfrica were onchocerciasis fociinMali and Senegal in
the Western Extension area of the OCP where treatment started in
1988 and 1989, shortly after the registration of ivermectin for the
treatment of human onchocerciasis in 1987. Although part of the
OCP, vector control was never used in this section of the Western
Extension area and ivermectin has been the sole intervention tool
since the start of control. A detailed review in 2001 of the available
evidence on the impact of ivermectin treatment on onchocerciasis
transmission in West and Central Africa showed that the prevalence
of infection had fallen to very low levels after 12 years of treatment
in onchocerciasis foci in Mali and Senegal in the Western extension
area of the OCP [21]. The long period of treatment and the
observed decline in prevalence of infection suggested that these foci
would be among the first areas where the hypothesis of whether
onchocerciasis can be eliminated with ivermectin from endemic foci
in Africa could be tested. A longitudinal study was therefore started
in 2005 in three initially hyperendemic onchocerciasis foci in Mali
and Senegal to undertake a detailed assessment of the residual levels
of infection and transmission, and, if sufficiently low, test whether
ivermectin treatment could be safely stopped. The first results of this
study are reported here.
Methods
Study sites
The three study areas are located along the River Bakoye in
Mali, the River Gambia in Senegal, and the River Faleme on the
border of the two countries (figure 1). The study areas were
selected on the basis of the following criteria: (i) they were part of
the Western Extension area of the OCP where onchocerciasis
control has been exclusively based on ivermectin treatment; (ii)
ivermectin treatment started in 1988–1989 and the area was part
of the first large-scale ivermectin treatment programs launched
after registration of the drug in 1987; (iii) there existed good
epidemiological baseline data for at least 10 villages where pre-
control skin snip surveys had been undertaken by the OCP using
standard onchocerciasis survey methods; (iv) the area contained
hyperendemic villages, i.e. villages with a prevalence of micro-
filaridermia $60% or a Community Microfilarial Load (CMFL,
the geometric mean number of microfilariae per skin snip among
adults aged 20 years and above) .10 microfilariae per skin snip
(mf/s) [22–24]; (v) the area was located along a river with known
breeding sites of Simulium damnosum s.l., and has a length of at least
100 kilometers along the river and a width of at least 15 km at
each side of the river. All three selected study areas met these
criteria. An additional reason for including the River Gambia area
was that it was the only area in Africa where six-monthly
treatment with ivermectin had been given for more than 10 years.
Demographically, the three study areas were similar with a rural
population in 2006 of 20,000 to 30,000 people living in 75 to 94
villages per site (table 1). In the R. Gambia focus there is also one
town with a population of about 18,000 but there are no urban
settlements in the other two study areas.
De Sole et al. [25,26] have mapped the pre-control distribution and
severity of onchocerciasis in the Western Extension of the OCP,
including all of Senegal and western Mali. According to their results,
the selected study areas along the River Gambia and the River Bakoye
were the two areas with the highest level of onchocerciasis endemicity
in Senegal and western Maliwhere there wasa high risk of onchocercal
blindness. Along the River Faleme there was also an appreciable risk of
onchocercal blindness along the southern part of the river where the
study site is located. All three study sites were mapped in detail by the
OCP and figures 2a, 3a and 4a show for each of the sites the spatial
Author Summary
The control of onchocerciasis, or river blindness, is based
on annual or six-monthly ivermectin treatment of popu-
lations at risk. This has been effective in controlling the
disease as a public health problem, but it is not known
whether it can also eliminate infection and transmission to
the extent that treatment can be safely stopped. Many
doubt that this is feasible in Africa. A study was
undertaken in three hyperendemic onchocerciasis foci in
Mali and Senegal where treatment has been given for 15
to 17 years. The results showed that only few infections
remained in the human population and that transmission
levels were everywhere below postulated thresholds for
elimination. Treatment was subsequently stopped in test
areas in each focus, and follow-up evaluations did not
detect any recrudescence of infection or transmission.
Hence, the study has provided the first evidence that
onchocerciasis elimination is feasible with ivermectin
treatment in some endemic foci in Africa. Although further
studies are needed to determine to what extent these
findings can be extrapolated to other areas in Africa, the
principle of onchocerciasis elimination with ivermectin
treatment has been established.
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Onchocerciasis was endemic throughout the study areas, and in each
area there were several hyperendemic villages. In the River Gambia
focus, 8 out of 22 surveyed villages had a CMFL.10 mf/s (range 12.0
to 48.1 mf/s) [26]. In the River Bakoye focus 5 out of 11 surveyed
villages had a CMFL.10 mf/s (range 10.2 to 21.6 mf/s) and in the
River Faleme focus this was the case for 3 out of 27 surveyed villages,
which had CMFL’s of 13.3, 16.0 and 21.0 mf/s respectively.
All three onchocerciasis foci are isolated with respect to long-
distance migration of the Simulium vectors except for the first few
Table 1. Ivermectin treatment history in the three study areas.
River Gambia (6-monthly Rx*) River Bakoye (annual Rx) River Faleme (annual Rx)
Geographic treatment coverage (year/no. villages treated)
First year with ivermectin treatment 1988/20 1989/28 1989/6
First year with all 1
st line villages treated 1990/30 1992/66 1991/61
First year with all villages treated 1992/79 1993/72 1993/87
Last year with all villages treated** 2006/83 2006/75 2006/94
Total years of treatment of all 1
st line villages 17 years 15 years 16 years
Therapeutic coverage in treated villages
1988 to 1991 64%–69% 59%–62% 63%–68%
1992 to 1996 76%–77% 75%–78% 77%–81%
1998 to 2006 77%–81% 73%–83% 79%–89%
*Annual treatment in 1988 and 1989; 6-monthly from 1990 onwards.
**Increase in number of villages due to establishment of new villages.
doi:10.1371/journal.pntd.0000497.t001
Figure 1. Location of the three study areas in Mali and Senegal.
doi:10.1371/journal.pntd.0000497.g001
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flow and there are no blackflies. At the beginning of the rainy
season, when the Inter-tropical-conversion-zone (ITCZ) moves to
the north, the breeding sites are reinvaded by simuliids from the
south (mainly S. sirbanum) that migrate with the prevailing winds
and start the repopulation of the breeding sites [27–29]. After a
few weeks, when the winds change, this long distance migration
stops and the vector population becomes purely local with virtually
Figure 2. Prevalence of onchocerciasis infection in the R. Gambia focus.
doi:10.1371/journal.pntd.0000497.g002
Figure 3. Prevalence of onchocerciasis infection in the R. Bakoye focus.
doi:10.1371/journal.pntd.0000497.g003
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end of the rainy season, reverse migration takes place with
blackflies from the study sites moving with the winds to perennial
rivers in the south. All river basins involved in this migration
pattern are either free from onchocerciasis or under large-scale
ivermectin treatment since 1990. For the R. Bakoye, S. dieguerense
has also been reported but this is a non-migratory Simulium species
that only plays a local role in onchocerciasis transmission [30].
The three study areas are not completely isolated from
neighboring endemic areas. Along all three rivers there are
onchocerciasis endemic villages downstream of the study areas but
their endemicity levels are generally lower and they are all covered
by the same national ivermectin treatment programs of Mali and
Senegal. The neighboring river basins are also endemic for
onchocerciasis and undergoing ivermectin treatment. Although
there is little vector migration between the river basins, human
migration cannot be excluded. Upstream in Guinea there are
some endemic areas that are also reported to be under ivermectin
treatment. Hence, the three study areas cannot be considered
completely isolated areas, but rather as the most endemic sections
of onchocerciasis zones along three rivers that are fully covered by
the national ivermectin treatment programs.
Ivermectin treatment history
Ivermectin treatment started first in 1988 in the R. Gambia focus
as part of the community trials of ivermectin undertaken by the
OCP to confirm the safety of large-scale ivermectin treatment [31],
and in 1989 in the other two foci (table 1). Treatment was not
immediately introduced in all villages in the three areas but first
targeted at the most affected villages. During the next 5 years the
treatment program was gradually expanded until it covered all
villages. As a result of this stepwise introduction of treatment, the
number of years that each village had received treatment by the
time of the study ranged from 14 to 19 years. From an
epidemiological point of view, the most significant period was when
all first-line villages, located near the river and the vector breeding
sites and which play a dominant role in onchocerciasis transmission
[32], were treated. This was achieved for the R. Gambia from 1990
onwards, for the R. Bakoye from 1992 onwards and the R. Faleme
from 1991 onwards. Hence, by the end of 2006, all first-line villages
inthe R.Gambia areahadbeen undertreatmentfor17years,inthe
R. Bakoye area for 15 years, and in the R. Faleme area for 16 years.
We will use those numbers when referring to the number of years of
ivermectin treatment in each study area. In the R. Gambia focus,
treatment was given at six-monthly intervals from 1990 onwards,
and the number of treatments pervillage ranged from 30 to 36,with
all first-line villages receiving at least 34 treatments. The urban area
was excluded from treatment in accordance with national treatment
policy. In the other two basins treatment was given annually in all
villages.
Initially, ivermectin treatment was ensured by mobile teams of
the Ministry of Health. The reported treatment coverage during
the first three years was not very high but subsequently improved
and reached between 75 to 81% of the total population between
Figure 4. Prevalence of onchocerciasis infection in the R. Faleme focus.
doi:10.1371/journal.pntd.0000497.g004
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treatment was changed from the costly mobile-team approach to
Community-directed Treatment with ivermectin (CDTi) [2]. The
new policy was introduced rather abruptly while there was some
resistance from health workers who would no longer benefit from
the financial support that OCP provided for mobile teams. As a
result, there was a fall in treatment coverage during the transition
year of 1997. In 1998, the situation was corrected and following
proper social mobilization efforts, CDTi took off effectively. A
second implication of the change from mobile teams to CDTi was
the integration of treatment reporting into the national health
information systems. This was initially problematic and for several
years the available records were incomplete (and largely missing
for 1997) until the new system was properly functioning. The
change to CDTi resulted in a further improvement of treatment
coverage which in several years even exceeded 80% of the total
population (about 95% of eligibles). Overall, the reported
treatment coverage has been high since 1992 with the exception
of the year 1997.
Study design
Onchocerciasis elimination is here defined as the reduction of
local onchocerciasis infection and transmission to such low levels
that transmission can no longer sustain itself and treatment can be
safely stopped without risk of recrudescence of infection and
transmission. Surveillance would still be needed to detect possible
reintroduction of the parasite through human or vector migration
from other endemic areas where elimination has not yet been
achieved.
To assess whether elimination has been achieved in the three
study areas, the study was designed in three phases (figure 5). The
aim of the first phase was to undertake a detailed assessment of
onchocerciasis infection and transmission levels after 14 to 17
years of treatment. Skin snip surveys were to be undertaken in a
stratified random sample of some 40 villages in each study site, and
transmission would be monitored for a full transmission season
through entomological evaluations in 4 to 6 fly-catching points per
study site. If the observed infection and transmission levels in a
study site were below predefined, provisional thresholds (see
section on indicators below), phase 2 would start in which
treatment would be stopped in a test area of 5–8 villages located
around one of the catching points in the study site. The effect of
stopping treatment on infection and transmission would be
evaluated by epidemiological surveys 20 to 22 months after the
last treatment in the test villages, and by entomological evaluation
in all catching points during another full transmission season. If
there was no recrudescence of infection and transmission in the
test area, phase 3 would start in which treatment would be stopped
throughout the study site and infection and transmission
monitored for another two years in all sample villages and
catching points. The first two phases of the study have been
completed in all three study sites.
Epidemiological evaluation methods
At the beginning of the study, all villages located in the study
area were visited to obtain exact geographic coordinates using a
geographic positioning system (GPS). These coordinates were used
to generate exact maps of the study areas, and using these maps a
spatial sample of at least 40 villages were selected to be surveyed
during the first phase of the study. Of these 40 villages, 20 were
selected from the first-line villages along the river, while ensuring a
good spatial coverage along the length of the river basin, and the
remaining 20 villages selected randomly from the second line or
further away from the breeding sites. Skin snip surveys were done
in all selected villages 11–12 months after the last treatment round.
A few selected villages proved to be very small (,50 people), and
for those the nearest village was also included in the surveys.
In each village, all persons above the age of 1 year who agreed
to participate (or whose parent agreed for them to participate in
the case of children) were examined for onchocerciasis infection.
The surveys used established skin snip examination methods in
which the national onchocerciasis teams have been trained in the
past by the OCP. Two skin snips were taken from the iliac crests
with a 2 mm Holth corneoscleral punch and microscopically
Figure 5. Study design and study phases in each study site.
doi:10.1371/journal.pntd.0000497.g005
Onchocerciasis Elimination with Ivermectin
www.plosntds.org 6 July 2009 | Volume 3 | Issue 7 | e497examined after incubation for 30 minutes in distilled water (and a
further 24 hours in saline for negative skin snips) for the presence
and number of O. volvulus microfilariae [33]. The numbers of
microfilariae were counted and the results recorded for each
person examined. Basic information on the migration history for
each person during the last 10 years before the survey was also
collected.
During phase 2, treatment was stopped in test areas of 5–8
villages located around one of the catching points. Skin snip
surveys were done in all test villages 20–22 months after the last
treatment in 2006. During these surveys, an additional diagnostic
test was also used. This was an improved version of the traditional
diethylcarbamazine-citrate (DEC) patch test [34] that had recently
been developed by LTS Lohmann Therapie-Systeme AG and
undergone successful clinical testing at the Onchocerciasis
Chemotherapy Research Centre in Hohoe (OCRC), Ghana (K.
Awadzi, personal communication). The new test uses transdermal
technology for the application of a low dose of 5.4 mg of DEC-
citrate on the skin which produces within 24 hours a characteristic
skin reaction in persons infected with O. volvulus. The new patch
test was applied at the same time as the skin snip examination.
Patients were requested to return 24 hours later when the patch
was removed and the skin examined. A positive skin reading was
defined as the presence of a characteristic skin lesion consisting of
mild edema of the area covered by the patch, studded by fine
pinpoint papules. Before the surveys, all examiners were trained by
a senior technician from OCRC in the application of the DEC
patch test, and in standardized reading of skin reactions.
Entomological evaluation of onchocerciasis transmission
During each phase, a detailed entomological evaluation was
done throughout the full transmission season in order to determine
the levels of O. volvulus transmission. Four vector catching points
were selected per study area (six for the river Faleme which covers
a larger area and in two countries). Every week, 3 days of capture
were carried out at each catching point during the transmission
period which generally covers 4 to 5 months per year (June–
October or July–October). Flies were collected using the method
of bulk catches with a team of 3 to 4 fly catchers working from 7
AM to 6 PM. Each daily catch was preserved in 80% alcohol and
sent to the DNA laboratory of the Multi-Disease Surveillance
Centre (MDSC) in Ouagadougou, Burkina Faso [35]. In the
laboratory, the flies were rinsed with distilled water, the heads
separated from the bodies and sorted in lots for DNA extraction.
The purified DNA was used as a substrate in a O-150 (an
Onchocerca-specific DNA sequence) PCR, and the resulting product
classified by hybridization to the O. volvulus-specific oligonucleotide
probe OVS-2 [36,37]. A computer program (Poolscreen
TM) was
used to translate the molecular biology data obtained from
screening pools into an estimate of the infectivity rate in the vector
population [37].
Indicators
The two main indicators of onchocerciasis infection and
transmission used in the present study are the vector infectivity
rate as measured by the number of flies with O. volvulus L3
(infective) larvae in the head per 1,000 flies (FLH/1,000) and the
prevalence of microfilariae in the skin in the human population.
Model predictions as well as large-scale experience in the OCP
had shown that these indicators do not have to be equal to zero to
ensure elimination, but that there are thresholds below which
infection and transmission will die out [38–40]. Computer
simulations with the model ONCHOSIM predicted that the risk
of recrudescence was negligible if the vector infectivity rate was
below 0.9 to 1.3 FLH per 1,000 parous flies and the OCP adopted
therefore a threshold of 1 FLH per 1,000 parous flies [41]. When
after 14 years of vector control, onchocerciasis elimination
appeared to have been achieved in the original OCP area, it
was decided to stop vector control operations in nine river basins.
To ensure that the decision to stop had been correct, a large scale
entomological evaluation was undertaken during the first two
years after stopping vector control [39]. The results showed that
there were still infective flies in each river basin but at levels below
the threshold of 1 FLH per 1,000 parous flies. Definite evidence
that the decision to stop vector control had been correct was
provided by epidemiological surveys undertaken 10 years after the
cessation of control which showed that there had been no
recrudescence of infection [38,42].
The entomological evaluation methods used by the OCP
involved dissection of hundreds of thousands of flies, which was
technically and financially highly demanding and difficult to
sustain by the countries alone after the closure of the OCP in
2002. When pool screening became operational in 1998, it was
made the standard method for entomological surveillance of
onchocerciasis transmission by national onchocerciasis control
programs in the OCP countries, supported by the MDSC [43]. In
this approach, black flies are collected by village members for the
full transmission season and subsequently forwarded through the
national onchocerciasis control programs to the MDSC molecular
biology laboratory in Ouagadougou for analysis [44]. As no fly
dissections are done in the field, the proportions of parous flies are
not known. The threshold of 1 FLH per 1000 parous flies was
therefore converted by the OCP to a threshold of 0.5 FLH per
1,000 flies, assuming an average parous rate of about 50% over the
transmission season [45]. The pool screen method and the
corresponding threshold appear to have worked well for
entomological surveillance in West Africa since 1998, confirming
that transmission levels remained insignificant in most river basins
but having detected residual transmission in a few areas where
control was known to have been unsatisfactory. The same
standard pool screening method with a pool size of 300 flies and
threshold of 0.5 FLH per 1,000 flies were used in the current
study. To ensure that a sample with 0 FLH would imply that the
infectivity rate was with 95% confidence below the threshold of 0.5
FLH per 1000 flies, a minimum of 3900 flies was to be analyzed
per catching point [37].
The provisional thresholds for the prevalence of infection in the
current study were also defined on the basis of the experience with
successful cessation of vector control in the OCP. Just before
stopping control, the OCP had undertaken skin snip surveys in
eleven initially hyperendemic villages from the nine river basins.
Four of the villages had become skin snip negative but seven
villages still had a prevalence of infection between 1.0% and 4.8%
[39]. Guided by these data, the provisional thresholds for
elimination with ivermectin treatment in the present study were
conservatively defined as a microfilarial prevalence ,1% in 90%
of sample villages, and a prevalence ,5% in 100% of sample
villages.
The above thresholds were provisional thresholds to guide
decision making and analysis in the current study. One of the
objectives of the study is to review these thresholds, and revise
them as required, in a detailed model-based analysis of the final
study results.
Research ethics
Ethical review and clearance of the research protocol, research
instruments and informed consent procedures were obtained from
the national ethical review boards of the ministries of health in
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(WHO) ethical review committee. Community meetings were held
in all villages to explain the research objectives and procedures,
and the right of each individual to decide whether to participate in
the examinations or not. Before each examination, each individual
who had voluntarily come to the examination point and agreed to
participate signed, or put a thumb print if not literate, on the
examination form to indicate consent. For children, one of the
parents or the responsible guardian would sign the examination
form. The use of community meetings to discuss the research
project and the right of individuals to refuse participation in the
examination was considered the most culturally appropriate and
effective method for providing the necessary information to
community members, and this approach was approved by both
the national ethical review boards and the WHO ethical review
committee.
Results
Onchocerciasis infection and transmission after 14 to 17
years of ivermectin treatment
During phase 1, epidemiological evaluations were done in 126
villages between mid March to mid May 2006, just before the last
full treatment round in April and May 2006 (table 2). A total of
17,890 persons (71.1% of the census population) voluntarily came
to the examination points and agreed to participate in the skin snip
examination. Those who did not participate included 11.3% of the
census population who were absent from the village for up to one
year, and 17.6% who were in the village but did not come to the
examination for reasons of non-eligibility (age,1 year), advanced
age or illness, or who refused to participate. Information on refusal
was obtained indirectly from family or other community members,
indicating that some 9% of the census population refused to
participate in the skin snip examination.
The results of the evaluations showed that 14 to 16 years of
ivermectin treatment had fundamentally changed the epidemio-
logical situation in all three study areas (figures 2 to 4). While
onchocerciasis was highly endemic during the pre-control period
in the R. Gambia area, after 16 years of treatment only 3 out of
5,271 persons examined were skin snip positive and 98% of
villages had a microfilarial prevalence ,1%. A similar change was
seen in the R. Bakoye where the prevalence in this previously
hyperendemic focus had dropped to 0.26% and 95% of villages
had a microfilarial prevalence ,1%. It is noteworthy that 13 of the
18 skin snip positives in the R. Bakoye focus came from one third-
line village. Further investigation revealed that the families
concerned lived most of the year on their farms on the river
banks, far away from their village but close to the vector breeding
sites. Because of the distance to the village, most of them had never
or only once been treated with ivermectin. Their skin microfilarial
loads were generally low except for two persons, one male of 32
years who was never treated and one boy of 10 years who was
treated once, and who had microfilarial loads of 87 mf/s and
96 mf/s respectively. Along the R. Faleme the epidemiological
results were equally good in the north and in the center of the
study area, with only 11 infected persons in 31 villages examined.
However, in the southern third of the focus there were still seven
villages with a microfilarial prevalence between 1% and 13%: 4
villages in Mali with a total of 15 infected persons and 3 villages in
Senegal with 22 infected persons.
Following the last full treatment round of early 2006 (and thus
after 15 to 17 years of treatment), entomological evaluations of
onchocerciasis transmission were undertaken during the rainy
season from July to November 2006. The results are summarized
in table 3. A total of 157,500 black flies were collected through the
bulk catches method and examined in the molecular biology
laboratory in Ouagadougou using the pool screening technique
[37,44]. For all catching sites the number examined exceeded the
target of 3,900. The results showed that onchocerciasis transmis-
sion levels were extremely low in all three river basins. In seven of
the catching points, not a single infective larva was detected. In the
remaining five catching points, the vector infectivity rate was
below the threshold of 0.5%. The location of the catching points is
shown in figure 6. Two catching points in Senegal, Yamoussa
along the R. Gambia, and Bambadji along the R. Faleme, were for
logistic reasons not yet operational in phase 1. For the others,
figure 6 also shows the vector infectivity rate.
Both in the R. Gambia and the R. Bakoye areas all
epidemiological and entomological indicators were below the
provisional thresholds for elimination. In R. Faleme area, the
epidemiological results for the center and north of the area were
below the threshold, as were the infectivity rates for all catching
points. Based on these results, it was decided to proceed with phase
2 of the study and stop treatment in test areas in each of the three
study foci.
Onchocerciasis infection and transmission after stopping
ivermectin treatment in test areas
Following the decision to proceed with the cessation of
treatment, test areas were identified in each of the study areas
(figures 7 to 9). Each test area consisted of 5 to 8 villages located
around a catching point, and included at least one village that had
a skin snip positive person in the phase 1 surveys. Treatment was
stopped in all villages in the test areas and during the next
treatment round in 2007, ivermectin treatment was only given in
the study villages outside the test areas. The impact of stopping
ivermectin treatment on infection and transmission was evaluated
by epidemiological surveys that were undertaken in January and
February 2008, i.e. 20 to 22 months after the last treatment in the
Table 2. Results of epidemiological evaluations after 14–16 years of treatment.
Study
area
Ivermectin
treatment
# villages
surveyed
Census
population Skin snip examination
Percentage of survey
villages with
Examined Mf+ve Prevalence
Geometric mean
mf/s in mf+ves Prev.mf,1% Prev.mf,5%
R. Gambia 6-monthly 42 7,184 5,271 3 0.06% 2.3 98% 100%
R. Bakoye Annual 40 9,868 6,899 18 0.26% 10.3 95% 100%
R. Faleme Annual 44 8,106 5,720 48 0.84% 5.8 80% 91%
doi:10.1371/journal.pntd.0000497.t002
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during the transmission season of 2007.
The results of the epidemiological evaluation are summarized in
table 4. This time only 55% of the census population came
voluntarily to be examined, 22% were absent from the village, 5%
were not eligible or could not come because of advanced age or
illness, and 28% of the population refused to be examined.
A total of 2,283 people were examined in 21 test villages, and all
of them were skin snip negative. The same result was obtained with
the DEC patch test for which also everybody was negative in all
three study sites. The numbers examined with the DEC patch test
are lower than those with the skin snip method in two of the study
areas because of people not returning after 24 hours for the follow-
up examination. Furthermore, up to one third of the patches had
partly or completely detached during the 24-hour follow-up period.
The few persons who were skin snip positive during phase 1 in these
tests villages had become skin snip negative or could not be
examined because of their absence from the village.
The entomological evaluation was done from mid August 2007
to mid December 2007, i.e. 16 to 20 months after the last
treatment in the test areas. Again, a very large number of 123,000
black flies was collected through bulk catches and examined in the
molecular laboratory in Ouagadougou. For all but one catching
points the number examined largely exceeded the target of 3,900
flies (table 5). The results showed that overall the vector infectivity
rate was even lower than in phase 1.
Figures 7 to 9 show the location of the catching points and the
surrounding villages in the test areas. The vector infectivity rates at
the catching points in the test areas were zero in all three study
sites, as well as in most other catching points. Only in two catching
points in the R. Faleme focus were infective larvae detected but the
infectivity rate was again below the threshold of 0.5 FLH/1,000.
Figure 6. Vector infectivity rates in the three study areas after 15 to 17 years of ivermectin treatment.
doi:10.1371/journal.pntd.0000497.g006
Table 3. Results of entomological evaluations after 15–17 years of treatment.
Study area Country Fly Catching Point Number of flies examined Infectivity rate (%) 95% Confidence interval (%)
R. Gambia Senegal Bantacokouta 15,900 0.063 0.002 0.327
Senegal Sekoto 21,300 0 0 0.090
Senegal Soukouta 3,900 0 0 0.492
R. Bakoye Mali Badala 10,200 0.202 0.002 0.709
Mali Kolontan 5,400 0 0 0.355
Mali Tieourou 18,000 0.230 0.044 0.667
Mali Toufinko 12,000 0 0 0.150
R. Faleme Mali Fadougou 19,500 0 0 0.098
Mali Mahina Mine 18,300 0.110 0.013 0.390
Mali Manankoto 14,100 0 0 0.130
Mali Satadougou 14,400 0 0 0.130
Senegal Saroudia 4,500 0.229 0.007 1.180
TOTAL 157,500
doi:10.1371/journal.pntd.0000497.t003
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were below the provisional elimination thresholds, and it has
therefore been decided to proceed with phase 3. Treatment has
now been stopped in all villages in the R. Gambia and R. Bakoye
study areas. Because of the less satisfactory epidemiological results
in the southern part of the R. Faleme, it was decided to proceed
Figure 7. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R.
Gambia focus.
doi:10.1371/journal.pntd.0000497.g007
Figure 8. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R.
Bakoye focus.
doi:10.1371/journal.pntd.0000497.g008
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section of the focus where treatment has been stopped first and will
be evaluated for one year before a final decision is taken to stop
treatment in all villages throughout the focus.
Discussion
Ever since ivermectin became the principal tool for onchocer-
ciasis control, it has been debated whether, in addition to
controlling the disease as a public health problem, it could also
be used to interrupt transmission and eliminate the parasite
[11,18]. As the drug does not kill or permanently sterilize the adult
worms, elimination was clearly not possible in the short term.
However, it was not unreasonable to assume that sustained
interruption of transmission could be achieved after a long period
of mass treatment. The first community trials had shown that mass
treatment with ivermectin significantly reduces transmission and
thus the incidence of infection with new worms [46–49]. It was
likely, therefore, that repeated mass treatment would result in a
progressive reduction in transmission of the parasite, probably
accelerated by an additional effect of ivermectin treatment on the
fertility of the adult worm [15]. Model predictions had indicated
that elimination might be possible [16], but empirical longitudinal
data were not yet available to test this prediction and there
remained considerable uncertainty as to whether elimination
could be achieved, especially in Africa where the disease is
endemic over large areas and where the vectors are highly efficient
[18]. The current study has provided the first evidence that
Figure 9. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R.
Faleme focus.
doi:10.1371/journal.pntd.0000497.g009
Table 4. Results of epidemiological evaluations 20-22 months after the last treatment in the test areas.
Study area
Ivermectin
treatment
# villages
surveyed
Census
population Skin snip examination DEC patch test
Examined Mf+ve Prevalence Examined +ve Prevalence
R. Gambia 6-monthly 8 1,136 775 0 0% 775 0 0%
R. Bakoye Annual 5 2,188 1,066 0 0% 933 0 0%
R. Faleme Annual 8 827 442 0 0% 408 0 0%
doi:10.1371/journal.pntd.0000497.t004
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in some endemic foci in Africa. After 15 to 17 years of annual or
six-monthly ivermectin treatment in three foci in Mali and
Senegal, only few infections remained in the human population,
infective O. volvulus larva were extremely rare in hundreds of
thousands black flies examined, and vector infectivity rates were
everywhere below the postulated threshold for interruption of
transmission.
The evidence generated after stopping treatment in test areas of
each focus was even more convincing. Evaluations conducted 16
to 22 months after the last treatment showed no recrudescence of
infection in the human population and no recrudescence of
transmission. In fact, not a single skin snip positive person or
infected black fly was detected in the test areas themselves. This is
a significant finding as one of the main uncertainties was whether
the residual adult parasite population was still sufficiently viable to
restart microfilarial production after the withdrawal of ivermectin.
The fact that no skin microfilariae were found up to 22 months
after the last ivermectin treatment indicates that even if there still
were adult worms in the human population, they were no longer
productive or produced too few microfilariae, to be detected by
the skin snip method, and posed therefore no significant risk for
onchocerciasis transmission.
A difficulty in the present study was to define the total treatment
periodin each studyarea. The treatment programswereintroduced
in a stepwise manner, covering during the first years the most
infected villages and gradually expanding coverage during subse-
quent years to villages with lower levels of endemicity. We have
definedthe effective treatmentperiodas the numberof years that all
first-line villages were included in the treatment program. These
villages are ‘first line’ towards the river with no other human
populations between them and the vector breeding sites, and they
play a dominant role in onchocerciasis transmission [32]. The
implication of this definition is that some first-line villages received
treatment for one or two more years than the overall treatment
period reported, and other villages that were deemed less important
for transmission received less years of treatment.
A unique feature of the current study is that it allowed a
comparison of the long-term impact of two different treatment
strategies: annual and six-monthly treatment. The final results in the
R. Gambia focus, where ivermectin treatment was given at six-
monthly intervals, and in the R. Bakoye, where treatment was
annual, were virtually identical. The prevalence of infection had
fallentoverylow levelsinbothareas,the vectorinfectivityrateswere
close to zero and, most importantly, there had been no
recrudescencein infection and transmission after stopping treatment
in the test areas. In the R. Faleme focus, where treatment was
annual, the evaluation results were equally good in the centre and
north of the focus, but in the south there werestill sevenvillages with
a microfilarial prevalence between 1% and 13%. A higher
prevalence in the south was seen both on the right bank of the
river in Mali and on the left bank in Senegal, suggesting that the
reason was of a spatial nature rather than related to treatment
coverage or strategy. The R. Faleme borders on Guinea in the south
and the results could be explained by some limited reinfection
originating from across the border. The critical question for
elimination, however, is whether the residual levels of infection in
the R. Faleme constitute a risk for recrudescence of transmission.
Vector infectivity rates were below the postulated threshold for
elimination inall catchingpointsintheR.Falemefocus,includingin
the south, and following cessation of treatment in the test area there
was no evidence of recrudescence. It appears that elimination has
also been achieved in the north and centre of the R. Faleme focus,
and possibly inthe south but this will be further investigated in2009.
From the perspective of elimination, therefore, the impact of 15–17
years of treatment was not very different between the three river
basins and the six-monthly treatment regimen did not show a clear
advantage over annual treatment. However, historical epidemio-
logical evaluation data of the OCP have shown that infection levels
in the R. Gambia initially fell much faster than in other river basins
[21] and it is quite possible that elimination was achieved several
years earlier in the area with six-monthly treatment.
Although the current study has provided the first evidence of
elimination with ivermectin treatment in onchocerciasis endemic
areas in Mali and Senegal, the results do not imply that
elimination is feasible in all other endemic areas in Africa. The
feasibility of elimination depends on several factors that may vary
significantly between onchocerciasis endemic areas, e.g. pre-
Table 5. Results of entomological evaluations 16–20 months after the last treatment in the test areas.
Study area Country Fly Catching Point Number of flies examined Infectivity rate (%) 95% Confidence interval (%)
R. Gambia Senegal Bantacokouta 8700 0 0 0.220
Senegal Sekoto 8400 0 0 0.228
Senegal Soukouta 10800 0 0 0.177
Senegal Yamoussou 6300 0 0 0.304
R. Bakoye Mali Badala 10800 0 0 0.177
Mali Kolontan 12300 0 0 0.156
Mali Tieourou 7220 0 0 0.266
Mali Toufinko 16800 0 0 0.114
R. Faleme Mali Fadougou 8400 0.121 0.003 0.624
Mali Mahina Mine 8400 0 0 0.228
Mali Manankoto 8400 0 0 0.228
Mali Satadougou 8100 0.186 0.0038 0.647
Senegal Saroudia 2700 0 0 0.711
Senegal Bambadji 5700 0 0 0.336
TOTAL 123000
doi:10.1371/journal.pntd.0000497.t005
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migration, and treatment factors of coverage, frequency, duration,
and efficacy.
Previous modeling studies have indicated that the probability of
elimination of onchocerciasis infection and transmission depends
strongly on the pre-control level of endemicity [16]. The
endemicity level reflects the density and competence of the local
vector population and the intensity of human-vector contact
during the pre-control period, and it is therefore an important
predictor of the local potential for transmission after cessation of
treatment. In all three river basins there were initially hyperen-
demic villages and their maximum intensity of infection, as
reflected by the CMFL, ranged from 22 to 48 mf/s. Although
these fall within the hyperendemic range, there are many
onchocerciasis foci in Africa where the level of endemicity is
significantly higher, and where elimination will probably be more
difficult to achieve.
Simulium species differ considerably in vector competence and
elimination is predicted to be more difficult when vector
competence is high [1,50]. The importance of vector competence
was already obvious during the first community trials of ivermectin
which showed a much greater reduction in onchocerciasis
transmission after ivermectin treatment in an onchocerciasis focus
in Guatemala, where the vector S. ochraceum s.l. has a relatively low
vector competence, than in community trials in Africa where the
vectors belonged to the S. damnosum complex [46–48]. In the study
areas in Mali and Senegal the main vector is S. sirbanum, which is
the most widely distributed vector in West Africa and the
predominant vector in the dry savanna. [1,30,51]. In the wet
savanna the distribution of S. sirbanum overlaps with that of S.
damnosum s.s. These two savanna species cannot be differentiated
morphologically and there exist only few studies that have
analyzed elements of vector competence for these two species
separately, showing no consistent difference between S. sirbanum
and S. damnosum s.s. [52,53]
Transmission is seasonal in the study sites in Mali and Senegal
and only takes place during the rainy season when the vectors have
repopulated the breeding sites. Seasonal transmission does not
necessarily imply less transmission than in areas where the vectors
are present throughout the year. In fact, the reverse is often true in
West Africa where the highest endemicity levels are found in areas
with seasonal rather than perennial transmission. But seasonal
transmission allows for a treatment strategy that optimizes the
impact of annual treatment on transmission by distributing
ivermectin just before the start of the rainy season. This ensures
that microfilarial loads are at their lowest during the transmission
season and that when they rise again there are no vectors around
to ingest such microfilariae.
The above characteristics of the study sites, i.e. seasonal
transmission by S. sirbanum and endemicity levels in the lower
range of hyperendemicity with CMFL’s between 10 and 20 mf/s,
and occasionally up to 40–50 mf/s, are typical for the dry savanna
belt in West Africa which runs from Senegal and Mali, through
northern Nigeria to Chad and Sudan [1,30,51,54]. This is a vast
area with millions of people infected with onchocerciasis, for
whom the study findings are directly relevant. However, more to
the south the vectors are different and there are many areas where
pre-control endemicity levels are higher and where elimination
may be more difficult. There is therefore an urgent need for
further investigations to determine to what extent the findings of
the current study can be extrapolated to other onchocerciasis
endemic areas in Africa.
Experience with vector control in the OCP has shown that long-
distance migration by infected simuliids from outside a control
program area can result in significant transmission within the area
under control [27]. The study areas in Mali and Senegal were not
subject to long-distance vector migration except for a short period at
the beginning of the rainy season when a new wave of simuliids
repopulated the breeding sites. However, the study foci were not
completely isolated from neighboring endemic areas. Along the rivers
there were other endemic villages beyond the boundaries of the study
areas and all neighboring river basins were endemic for onchocer-
ciasis. It is likely that there was some vector dispersal along the rivers
across the study boundaries as well as some human movement from
other endemic areas, but, with the possible exception of south
Faleme, this did not result in any significant infection or transmission
in the study areas. The reason is probably that all onchocerciasis
endemic areas in Senegal and western Mali have been treated by the
national ivermectin treatment programs of the two countries since the
early 1990s, irrespective of whether they fell within or outside the
boundaries of the current study, and that the epidemiological
situation was equally good (if not better because of lower pre-control
endemicity levels) outside the study areas. It is quite possible therefore
that onchocerciasis is near elimination in all of Senegal and western
Mali, and that nationwide elimination of onchocerciasis may be a
realistic target for these countries for the coming years.
With the exception of the year 1997, annual treatment coverage
was good throughout the control period and this is an important
reason for the results obtained. Onchocerciasis foci where
treatment coverage has been less good or where the geographic
coverage has been patchy, may require considerably more years of
treatment to achieve elimination. On the other hand, in this first
experimental cessation of ivermectin treatment ever, we have
proceeded very prudently and it is possible that equally satisfactory
results might have been obtained if treatment had been stopped a
few years earlier.
The study provided a unique opportunity to evaluate a new
diagnostic test in the field. The improved DEC patch test was easy
to use and was shown to be highly specific in these onchocerciasis
foci in West Africa. A high specificity is critically important for the
potential use of the test as an epidemiological tool in low
prevalence situations. The DEC patch test had some operational
shortcomings, i.e. the requirements to return for the examination
24 hours after application of the patch (due to the test measuring a
delayed hypersensitivity reaction to microfilarial antigens) which
led to the failure of some people to do so, and a considerable
proportion of patches having become partly or completely
detached during the 24-hour period. But these limitations do not
outweigh the great advantage that the DEC patch test, as a
noninvasive test, has over the skin snip examination in which the
populations of endemic areas are increasingly reluctant to
participate. This was also evident in the current study where a
quarter of the population refused to participate in the skin snip
examination during the second phase of the study. This high rate
of refusals might have introduced some bias in the epidemiological
evaluation, and it was therefore important to have a second,
independent source of evidence on interruption of transmission
from the entomological evaluation in the same locations.
The results of the study, indicating elimination after 15 to 17
years of annual or six-monthly ivermectin treatment, are quite
consistent with previous ONCHOSIM predictions on the feasibility
of elimination for comparable levels of endemicity, treatment
coverage and treatment frequency [16]. These predictions were
based on data from the first five years of ivermectin treatment only,
and a more detailed model-based analysis of the data of the current
study is being undertaken to develop improved predictions of where
and when ivermectin treatment canbe safely stopped. Furthermore,
the thresholds for elimination used in the current study are
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evaluations after cessation of vector control. A second objective for
the ongoing modeling research therefore is to review and revise the
elimination thresholds for ivermectin treatment on the basis of the
data from the current study.
The study in Mali and Senegal still continues. Following the
excellent results of the second phase, the third phase of the study
has now been started and will generate additional data on
onchocerciasis infection and transmission two to three years after
stopping treatment in all villages in the three onchocerciasis foci. If
the follow-up findings confirm the current results, they would
provide the definite evidence that it was safe to stop ivermectin
treatment and that onchocerciasis infection and transmission has
been eliminated from the three foci in Mali and Senegal.
In the meantime, the study has provided the first evidence that
onchocerciasis elimination with ivermectin treatment is feasible in
some endemic foci in Africa, and this has already introduced a new
paradigm for onchocerciasis control in the continent. Although this
first evidence does not yet imply that elimination with ivermectin
will be possible everywhere in Africa, the principle of elimination
has been established. It now becomes a priority to evaluate in all
onchocerciasis control programs in Africa their impact on
onchocerciasis infection and transmission, and their progress
towards elimination endpoints. The board of APOC has already
acted upon the preliminary results of this study and adopted an
additional objective for APOC to ‘‘develop the evidence base on
when and where ivermectin treatment can be stopped, and provide
guidance to countries on how to prepare for and evaluate cessation
of treatment where feasible’’ [55]. APOC has already started to
systematically collect epidemiological data on the impact of large-
scale ivermectin treatment on onchocerciasis infection in different
countries, focusing first on areas with the highest pre-control
endemicity levels and different vector species.
When large scale ivermectin treatment started in 1987, it was
not known if it would ever be possible to stop treatment. The
present study has provided the first evidence that this is possible
and that onchocerciasis elimination can be a realistic target, also in
endemic areas in Africa.
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